Yanji Luo

Dr. Yanji Luo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
BHBingsheng Huang
Bingsheng Huang
JTJunru Tian
Junru Tian
HZHongyuan Zhang
Hongyuan Zhang
ZLZixin Luo
Zixin Luo
Jing QinJing Qin
Jing Qin
CYChenglang Yuan
Chenglang Yuan
Recently, an emerging trend in medical image classification is to combine radiomics framework with deep learning classification network in an integrated system. Although this combination is efficient in some tasks, the deep learning-based classification network is often difficult to capture an effective representation of lesion regions, and prone to face the challenge of overfitting, leading to unreliable features and inaccurate results, especially when the sizes of the lesions are small or the training dataset is small. In addition, these combinations mostly lack an effective feature selection mechanism, which makes it difficult to obtain the optimal feature selection. In this paper, we introduce a novel and effective deep semantic segmentation feature-based radiomics (DSFR) framework to overcome the above-mentioned challenges, which consists of two modules: the deep semantic feature extraction module and the feature selection module. Specifically, the extraction module is utilized to extract hierarchical semantic features of the lesions from a trained segmentation network. The feature selection module aims to select the most representative features by using a novel feature similarity adaptation algorithm. Experiments are extensively conducted to evaluate our method in two clinical tasks: the pathological grading prediction in pancreatic neuroendocrine neoplasms (pNENs), and the prediction of thrombolytic therapy efficacy in deep venous thrombosis (DVT). Experimental results on both tasks demonstrate that the proposed method consistently outperforms the state-of-the-art approaches by a large margin.

1 June 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
XHXuefang Hu
Xuefang Hu
JGJian Guan
Jian Guan
YWYangdi Wang
Yangdi Wang
SSSiya Shi
Siya Shi
CSChenyu Song
Chenyu Song
YLYanji Luo
Yanji Luo
Objective: We aimed to provide ideas for clinicians, especially radiologists, for the diagnosis of multiple endocrine neoplasia (MEN) syndromes. Background: MEN syndromes include MEN1, MEN2, and MEN4 and usually involve 2 or more endocrine tumors. The MEN syndromes are a group of euchromatic dominant genetic diseases, and the main genes involved include MEN1 (MEN1), RET (MEN2), and CDKN1B (MEN4). Methods: In this article, involving 8 cases (4 cases of MEN1, 2 cases of MEN2A, 1 case of MEN2B, 1 case of MEN4) from our center, we introduced the disease spectrum, clinical manifestations (especially imaging findings), and related genes involved in each type of MEN syndromes. We also discussed the differential diagnosis between MEN and sporadic tumors and emphasized that MEN should be screened and the relevant required examinations. Conclusions: Considering that MEN syndromes involve multiple endocrine gland tumors and nonendocrine organ diseases, it is very important to identify potential patients early and perform multiple examinations on them, including biochemical and multitype, and multisite imaging examinations according to the disease spectrum of each type. Considering that this is a group of genetic diseases, both interviewing patients about their family history and genetic testing are also very important. Only in this way can a comprehensive and accurate diagnosis be made, enabling patients to receive appropriate treatment and improve their prognosis.

4 March 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SSSiya Shi
Siya Shi
CLChuxuan Lin
Chuxuan Lin
JZJian Zhou
Jian Zhou
LWLuyong Bs Wei
Luyong Bs Wei
MCMingjie Chen
Mingjie Chen
SFShi-Ting Feng
Shi-Ting Feng
Background: Occult peritoneal metastases (OPM) in patients with pancreatic ductal adenocarcinoma (PDAC) are frequently overlooked during imaging. The authors aimed to develop and validate a computed tomography (CT)-based deep learning-based radiomics (DLR) model to identify OPM in PDAC before treatment. Methods: This retrospective, bicentric study included 302 patients with PDAC (training: n=167, OPM-positive, n=22; internal test: n=72, OPM-positive, n=9: external test, n=63, OPM-positive, n=9) who had undergone baseline CT examinations between January 2012 and October 2022. Handcrafted radiomics (HCR) and DLR features of the tumor and HCR features of peritoneum were extracted from CT images. Mutual information and least absolute shrinkage and selection operator algorithms were used for feature selection. A combined model, which incorporated the selected clinical-radiological, HCR, and DLR features, was developed using a logistic regression classifier using data from the training cohort and validated in the test cohorts. Results: Three clinical-radiological characteristics (carcinoembryonic antigen 19-9 and CT-based T and N stages), nine HCR features of the tumor, 14 DLR features of the tumor, and three HCR features of the peritoneum were retained after feature selection. The combined model yielded satisfactory predictive performance, with an area under the curve (AUC) of 0.853 (95% CI: 0.790–0.903), 0.845 (95% CI: 0.740–0.919), and 0.852 (95% CI: 0.740–0.929) in the training, internal test, and external test cohorts, respectively (all P<0.05). The combined model showed better discrimination than the clinical-radiological model in the training (AUC=0.853 vs. 0.612, P<0.001) and the total test (AUC=0.842 vs. 0.638, P<0.05) cohorts. The decision curves revealed that the combined model had greater clinical applicability than the clinical-radiological model. Conclusions: The model combining CT-based DLR and clinical-radiological features showed satisfactory performance for predicting OPM in patients with PDAC.


22 August 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SSSiya Shi
Siya Shi
RLRuihao Liu
Ruihao Liu
JZJian Zhou
Jian Zhou
JLJiawei Liu
Jiawei Liu
HLHongxin Lin
Hongxin Lin
SFShi-Ting Feng
Shi-Ting Feng
Background: Tumor fibrosis plays an important role in chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC); however, there remains a contradiction in the prognostic value of fibrosis. The authors aimed to investigate the relationship between tumor fibrosis and survival in patients with PDAC, classify patients into high- and low-fibrosis groups, and develop and validate a CT-based radiomics model to non-invasively predict fibrosis before treatment. Materials and methods: This retrospective, bicentric study included 295 patients with PDAC without any treatments before surgery. Tumor fibrosis was assessed using the collagen fraction (CF). Cox regression analysis was used to evaluate the associations of CF with overall survival (OS) and disease-free survival (DFS). Receiver operating characteristic (ROC) analyses were used to determine the rounded threshold of CF. An integrated model (IM) was developed by incorporating selected radiomic features and clinical-radiological characteristics. The predictive performance was validated in the test cohort (Center 2). Results: The CFs were 38.22±6.89% and 38.44±8.66% in center 1 (131 patients, 83 males) and center 2 (164 patients, 100 males), respectively ( P =0.814). Multivariable Cox regression revealed that CF was an independent risk factor in the OS and DFS analyses at both centers. ROCs revealed that 40% was the rounded cut-off value of CF. IM predicted CF with areas under the curves (AUCs) of 0.829 (95% CI: 0.753-0.889) and 0.751 (95% CI: 0.677-0.815) in the training and test cohorts, respectively. Decision curve analyses revealed that IM outperformed radiomics model and clinical-radiological model for CF prediction in both cohorts. Conclusions: Tumor fibrosis was an independent risk factor for survival of patients with PDAC, and a rounded cut-off value of 40% provided a good differentiation of patient prognosis. The model combining CT-based radiomics and clinical-radiological features can satisfactorily predict survival-grade fibrosis in patients with PDAC.

29 July 2022 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
SSSi-Ya Shi
Si-Ya Shi
LWLiqin Wang
Liqin Wang
ZPZhenpeng Peng
Zhenpeng Peng
YWYangdi Wang
Yangdi Wang
ZLZhi Lin
Zhi Lin
YLYanji Luo
Yanji Luo
Patients with chronic pancreatitis often have irreversible pancreatic insufficiency before a clinical diagnosis. Pancreatic cancer is a fatal malignant tumor in the advanced stages. Patients having high risk of pancreatic diseases must be screened early to obtain better outcomes using new imaging modalities. Therefore, this study aimed to investigate the reproducibility of tomoelastography measurements for assessing pancreatic stiffness and fluidity and the variance among healthy volunteers. Forty-seven healthy volunteers were prospectively enrolled and underwent two tomoelastography examinations at a mean interval of 7 days. Two radiologists blindly and independently measured the pancreatic stiffness and fluidity at the first examination to determine the reproducibility between readers. One radiologist measured the adjacent pancreatic slice at the first examination to determine the reproducibility among slices and measured the pancreas at the second examination to determine short-term repeatability. The stiffness and fluidity of the pancreatic head, body, and tail were compared to determine anatomical differences. The pancreatic stiffness and fluidity were compared based on sex, age, and body mass index (BMI). Bland–Altman analyses (all P > 0.05) and intraclass correlation coefficients (all >0.9) indicated near perfect reproducibility among readers, slices, and examinations at short intervals. Neither stiffness (P = 0.477) nor fluidity (P = 0.368) differed among the pancreatic anatomical regions. The mean pancreatic stiffness was 1.45 ± 0.09 m/s; the mean pancreatic fluidity was 0.83 ± 0.06 rad. Stiffness and fluidity did not differ by sex, age, or BMI. Tomoelastography is a promising and reproducible tool for assessing pancreatic stiffness and fluidity in healthy volunteers.